Skip to Content
Merck

Molecular markers in ductal carcinoma in situ of the breast.

Molecular cancer research : MCR (2003-03-26)
Dale Porter, Jaana Lahti-Domenici, Aparna Keshaviah, Young Kyung Bae, Pedram Argani, Jeffrey Marks, Andrea Richardson, Amiel Cooper, Robert Strausberg, Gregory J Riggins, Stuart Schnitt, Edward Gabrielson, Rebecca Gelman, Kornelia Polyak
ABSTRACT

Gene expression patterns in ductal carcinoma in situ (DCIS), and in invasive, and metastatic breast tumors were determined using serial analysis of gene expression (SAGE). We used mRNA in situ hybridization to examine gene expression at the cellular level and immunohistochemistry on tissue microarrays to determine association between gene expression patterns and histopathologic characteristics of the tumors. We found that that the most dramatic transcriptome change occurs at the normal to DCIS transition, while there is no clear universal "in situ" or "invasive" tumor molecular signature. From the 16,430 transcripts analyzed, we identified only 5 and 11 that were preferentially up-regulated in DCIS and invasive tumors, respectively. The majority of invasive cancer specific SAGE tags correspond to novel genes. The genes we identified may define biologically and clinically meaningful subgroups of DCIS with a high risk of progression to invasive disease.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
TFF3 human, recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture
Pricing and availability is not currently available.